

## EuropaBio invited healthcare biotech SMEs to learn about EU Policy Priorities

### NEWS RELEASE

**Brussels, June 3, 2021** – EuropaBio organised an online info session for SMEs active within the healthcare biotechnology sector to learn about the key EU policies and their possible impact on their current business strategies. This was the second event organised under the [EuropaBio SME Platform](#) initiative.

EuropaBio's Healthcare Biotechnology team Bernard Grimm, Violeta Georgieva and Darren Kinsella gave an overview of some key ongoing initiatives–affecting healthcare biotechnology in the EU. Our experts reviewed the ongoing revision of the Orphan Medicinal Products Regulation and its impact on SMEs involved in researching new therapies for rare diseases, the EU IP Action Plan and the importance of intellectual property for small businesses, and the multi-layered Pharmaceutical Strategy for Europe. Participants had the chance to learn about the recently launched EuropaBio's Biopharmaceutical Strategy Group, a forum for members, where some of the key initiatives within the EU Pharmaceutical legislation revision will be addressed.

The event was moderated by Darren Kinsella, Healthcare Biotechnology Manager at EuropaBio.

Please click on the links to access the event's slides and [the recording](#).

The next online webinar **on funding for SMEs** will take place June 17, 2021. Please [register here](#).

### About the EuropaBio SME Platform

The SME platform is a community of SMEs across all sectors in Europe, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders.

**ENDS**



## Media contact

Dovilė Sandaraitė, Communications Manager

Email: [d.sandaraitė@europabio.org](mailto:d.sandaraitė@europabio.org)

## About EuropaBio

EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Read more about our work at [www.europabio.org](http://www.europabio.org).

